View Older Stories View More Recent Stories
-
AbbVie (ABBV) call put ratio 1.3 calls to 1 put on active volume of 34K contracts
-
What is the impact of U.S. tariffs on biopharma sector?
-
Abbvie (ABBV) PT Raised to $216 at Guggenheim
-
AbbVie (ABBV) Reports RINVOQ Received FDA Approval for Giant Cell Arteritis (GCA)
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)
-
AbbVie (ABBV) EPS Beats Consensus, Updates Guidance
-
AbbVie set to report Q1 results: Focus on Skyrizi, Rinvoq and Part D impact
-
AbbVie (ABBV) call put ratio 1.5 calls to 1 put with a focus on May 182.50
-
AbbVie (ABBV) Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE
-
AbbVie (ABBV) call put ratio 1.7 calls to 1 put into quarter results
-
Bernstein SocGen Group Reiterates Market Perform Rating on Abbvie (ABBV)
-
Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
-
Pharma stocks slide after Trump signals tariffs on sector
-
Goldman Sachs Assumes Abbvie (ABBV) at Neutral
-
AbbVie (ABBV) issues updated guidance
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Genmab (GMAB) to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (ABBV)
-
Erste Group Upgrades Abbvie (ABBV) to Buy (Friday pre-market)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
Abbvie (ABBV) PT Raised to $195 at Berenberg
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as They Enter Obesity
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as They Enter Obesity
-
Bernstein Reiterates Market Perform on Abbvie (ABBV) Following Gubra Agreement
-
Abbvie (ABBV) PT Raised to $223 at BofA Securities
-
AbbVie (ABBV) appoints CEO as Chairman of board
-
AbbVie (ABBV) Appoints CEO Robert A. Michael as Chairman of the Board of Directors
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.4% Yield
-
AbbVie's Allergan Aesthetics set to launch three new training centers in U.S.
-
AbbVie (ABBV) and Xilio Therapeutics (XLO) Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
-
AbbVie (ABBV) Announces FDA Approval of EMBLAVEO
-
Abbvie (ABBV) PT Raised to $215 at BMO Capital as 'Guidance Raise Gives More Confidence'
-
Abbvie (ABBV) PT Raised to $214 at Guggenheim
-
Abbvie (ABBV) PT Raised to $210 at Leerink Partners
-
Abbvie (ABBV) PT Raised to $220 at Raymond James
-
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
-
AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
-
AbbVie (ABBV) call put ratio 1.8 calls to 1 put into quarter results
-
AbbVie (ABBV) call put ratio 1.1 calls to 1 put into quarter results
-
Raymond James Reiterates Outperform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $227 as Piper Sandler 'Likes the Chances for Upside'
-
Abbvie (ABBV) PT Raised to $208 at Goldman Sachs
-
AbbVie (ABBV) Completes Acquisition of Nimble Therapeutics
-
AbbVie (ABBV) and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
-
Abbvie (ABBV) PT Lowered to $212 at Guggenheim
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as I&I Portfolio Sees New Avenues for Growth in 2025
-
AbbVie (ABBV) Falls 2% with Presentation at JPMorgan Ongoing

